Tyra Biosciences Appoints New Chief Medical Officer

TL;DR

Tyra Biosciences just hired a new CMO from Mirati Therapeutics to lead their clinical efforts.

AI Summary

On August 21, 2025, Tyra Biosciences, Inc. announced the appointment of Dr. Todd M. W. Green as Chief Medical Officer. Dr. Green brings extensive experience in clinical development and medical affairs, most recently serving as Senior Vice President and Chief Medical Officer at Mirati Therapeutics, Inc. This strategic hire is intended to bolster Tyra's leadership team as it advances its pipeline.

Why It Matters

The appointment of a new Chief Medical Officer is a significant leadership change that could impact the strategic direction and execution of Tyra Biosciences' drug development programs.

Risk Assessment

Risk Level: medium — Hiring a new CMO can signal shifts in strategy or pipeline focus, which carries inherent risks for a biotech company.

Key Players & Entities

• Tyra Biosciences, Inc. (company) — Registrant
• Dr. Todd M. W. Green (person) — Newly appointed Chief Medical Officer
• Mirati Therapeutics, Inc. (company) — Dr. Green's former employer
• August 21, 2025 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share TYRA Nasdaq Global Select

Filing Documents

• d15901d8k.htm (8-K) — 25KB
• 0001193125-25-185553.txt ( ) — 137KB
• tyra-20250821.xsd (EX-101.SCH) — 3KB
• tyra-20250821_lab.xml (EX-101.LAB) — 18KB
• tyra-20250821_pre.xml (EX-101.PRE) — 11KB
• d15901d8k_htm.xml (XML) — 4KB

Forward-Looking Statements

Forward-Looking Statements Tyra cautions you that statements contained in this report regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: expected reporting of initial results from the BEACH301 study and the timing thereof. Actual results may differ from those set forth in this report due to the risks and uncertainties inherent in our business, including, without limitation: potential delays in the commencement, recruitment, enrollment, data readouts and completion of clinical trials and preclinical studies; results from preclinical studies or early clinical trials not necessarily being predictive of future results; interim results of a clinical trial are not necessarily indicative of final results and one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, as follow-up on the outcome of any particular patient continues and as more patient or final data becomes available, including the risk that unconfirmed responses may not ultimately result in confirmed responses to treatment after follow-up evaluations; the potential for proof-of-concept results to fail to result in successful subsequent development of dabogratinib; later developments with the U.S. Food and Drug Administration (FDA) may be inconsistent with prior feedback from the FDA; our dependence on third parties in connection with manufacturing, research and preclinical testing; unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their development, regulatory approval, and/or commercialization; the potential for our programs and prospects to be negatively impacted by developments relating to our competitors, including the results of studies or regulatory determinations relating to our competitors; regulatory developments in the United

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. TYRA BIOSCIENCES, INC. Date: August 21, 2025 By: /s/ Alan Fuhrman Alan Fuhrman Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR